We would love to hear your thoughts about our site and services, please take our survey here.
Mr Big, the percentages are those in the treatment group, i.e. % of patients who scored 3 when admitted onto the trial.
Note the SNG figures add to 100% = 51(?) patients, I assume the placebo doesn't add to 100% because some died!
P3 Trial. I think it was Helen that pointed this out the other day:
75% of treatment group was at WHO score 4 in Phase II. P3 three is basically repeating what is already known and adding data.
They are testing whether double dose is more effective/beneficial, they are trialling new components, they are trialling outcomes across different clinical care settings and different cultures/race.
I hope this happens quick now.
Yep, I've signed up too.
PhilGekko - Safety Data? Its adds value to the safe use of SNG.
Looks like they are processing the trials for peer review. Probably didn't get processed before and not important enough until now.
Synairgen isn't a member (not listed in search return) - there are 71 pages / 15 members per page - I bet all the most advanced list are members! This could be the beginning of the push into the light.
Unfortunately - SNG isn't on the list of 40 Most Advanced COVID-19 Antiviral Candidates.
Don't really understand why - there are many that are phase I in this list. Also others at Phase II.
Anyone for a Phase III announced....
You were told.
It was in the Placing/Offer RNS - what do you think a national priority health study in the middle of a pandemic means.
My mistake -
Results of the General Meeting and the Open Offer announced - 2nd November
Admission of the Conditional Placing Shares and the Open Offer Shares to trading on AIM and commencement of dealings - 4th
Where applicable, expected date for CREST accounts to be credited in respect of Conditional Placing Shares and Open Offer Shares in uncertificated form - 4th
We're not expecting anything further until after the 4th November. The bulk of the placing is conditional so no additional money is available until then (the 15m firm placing share monies are already in). We will receive confirmation of placing and following that we should have some TR1s.
I suspect as part of the placing confirmation or shortly thereafter we will also here confirmation of IND submission plus any other relevant news. Things are obviously on-going - regardless we are in dead space until the placing is officially completed next week (which may then be fun).
Thanks Oxford, just thought I might have missed something! All good.
I honestly love and appreciate the research the guys are posting here (really helped me).
Was trying to follow the logic on the P3 prophylaxis trial meaning its SNG.
I followed the link s- I obviously missed the statement that said SNG is on this? This seems speculative to me?
The link showed the government is ''appointing' someone to run this trial with multiple 'products' being evaluated under it over the next two years.
I understand SNG could (should?) be one of these products but where/how is that confirmed?
Are we just jumping to conclusions or have I just missed the obvious. (I appreciate the holgate(?) 'slip' in all this).
If yes, who is paying for the trial? Going to get expensive - if gov then okay that's income.
I don't have Synairgen jump out at me when I google 'care home trial covid treatment'.
Lets keep it real here.
PhilGekko - Viagra isn't an urban legend:
Scientists at the pharmaceutical company Pfizer discovered the powers of Viagra (sildenafil citrate) by accident in the early Nineties during trials of a potential new angina drug named UK-92480
This is called an opportunity Risk which can occur during research projects - viagra is the perfect example of this! QED.
COVID has also realised opportunity risks for other companies, e.g. Amazon, tech companies, On-line retailing/shopping, although I doubt many had listed pandemics as such for their risks in online/technology investment cases. LOL
Tyla - pretty certain this has already been covered and is false. Synairgen cannot issue anything new (its more than shares) within 180 days - the restriction is on Synairgen not the shareholder.
It already had EUA so makes sense. Probably did this because of the WHO outcome, politics and (non) science in USA until Trump is gone.
Doc - I think anticipated price and availability of stock preclude this from happening, at least in the short term.
Longer term this might be an option for lower numbers where the patient is likely to progress into hospital and/or develop long covid. I say lets actually get this to the hospitalised patients first, (On admittance), then pre-hospitalised patients.
Hi Joey/pmjh,
I read the IND as different types, would the IND be of type Investigator or Treatment for the Trial and a separate IND (Emergency Use) for use where not yet authorised?
Investigator type requires 30 days whereas the Emergency type does not require 30days but assumes this wouldn't require a trial?
Looks like some gap between NYSE and AIM - 20p per share?? (Not in AIM favour)
Just quoted 749 to Buy and 751 to Sell??
Marketwatch saying $10 = approx. £7.70.
They are not Bonus Shares - it's an entitlement in an Open Offer.
If you do not complete the Corporate Action - they will disappear.
You have options (Do nothing, request entitlement, more than entitlement, less than entitlement) - You require monies held within the account to enable the purchase.
You are only entitled to the entitlement - you can request more but these will be scaled back based upon take up of the Open offer and the amount requested above.
Guess we find out tomorrow how much the US wants to buy BUR.
How does the excess shares usually get shared among those that apply for them - is it prorated on application or proportionately to shareholders. Assume that lots of people are going to ask for varying amounts above entitlement?